Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial

被引：0
|
作者：
Ergun, Yakup [1 ]
机构：
[1] Antalya City Hosp, Dept Med Oncol, TR-07080 Antalya, Turkiye
来源：
LANCET | 2024年 / 404卷 / 10450期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：337 / 338
页数：2
相关论文
共 50 条
  • [41] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2-Breast Cancer
    Kang, Connie
    TARGETED ONCOLOGY, 2024, 19 (02) : 289 - 296
  • [42] An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer
    Cheng, Shao-Xian
    Chen, Qiu-Chi
    Lin, Guo-He
    Han, Yan-Hong
    Wang, Bi-Cheng
    Dai, Yi
    Zhao, Yan-Xia
    MEDICINE, 2023, 102 (30) : E34486
  • [43] Sacituzumab govitecan in metastatic Breast Cancer Optimal Interaction: ADC-based Therapy and Radiotherapy
    Schoellmann, Claudia
    BREAST CARE, 2024, 19 (04) : 236 - 238
  • [44] Real-world outcomes of sacituzumab govitecan in breast cancer
    Singh, Vaishnavi
    Dhaibar, Hemangini
    Peddi, Prakash
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
    Spring, Laura M.
    Nakajima, Erika
    Hutchinson, Jennifer
    Viscosi, Elene
    Blouin, Gayle
    Weekes, Colin
    Rugo, Hope
    Moy, Beverly
    Bardia, Aditya
    ONCOLOGIST, 2021, 26 (10): : 827 - 834
  • [46] Sacituzumab Govitecan, combination with PARP inhibitor, Talazoparib, in metastatic triplenegative breast cancer (TNBC): Translational investigation
    Bardia, Aditya
    Coates, James T.
    Spring, Laura
    Sun, Sheng
    Juric, Dejan
    Thimmiah, Nayana
    Niemierko, Andrzej
    Ryan, Phoebe
    Partridge, Ann
    Peppercorn, Jeffrey
    Parsons, Heather
    Wander, Seth
    Pierce, Kelsey
    Attaya, Victoria
    Fitzgerald, Donna
    Lormil, Brenda
    Shellock, Maria
    Nagayama, Aiko
    Bossuyt, Veerle
    Moy, Bev
    Tolaney, Sara
    Ellisen, Leif
    CANCER RESEARCH, 2022, 82 (12)
  • [47] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
    Hanna, Daire
    Merrick, Sophie
    Ghose, Aruni
    Devlin, Michael John
    Yang, Dorothy D.
    Phillips, Edward
    Okines, Alicia
    Chopra, Neha
    Papadimatraki, Elisavet
    Ross, Kirsty
    Macpherson, Iain
    Boh, Zhuang Y.
    Michie, Caroline O.
    Swampillai, Angela
    Gupta, Sunnia
    Robinson, Tim
    Germain, Lewis
    Twelves, Chris
    Atkinson, Charlotte
    Konstantis, Apostolos
    Riddle, Pippa
    Cresti, Nicola
    Naik, Jay D.
    Borley, Annabel
    Guppy, Amy
    Schmid, Peter
    Phillips, Melissa
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
  • [48] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [49] Primary Results of TROPiCS-02: A Randomized Phase 3 Trial of Sacituzumab Govitecan vs. Physician's Treatment of Choice (TPC) in Patients with Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer
    Marme, F.
    Rugo, H. S.
    Bardia, A.
    Cortes, J.
    Schmid, P.
    Loirat, D.
    Tredan, O.
    Ciruelos, E.
    Dalenc, F.
    Gomez, Pardo P.
    Jhaveri, K.
    Delaney, R.
    Fu, O.
    Lin, L.
    Verret, W.
    Tolaney, S. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 105 - 105
  • [50] New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 723 - 725
12345